SG11202000996UA - Antibody-drug conjugate preparation and lyophilization for same - Google Patents

Antibody-drug conjugate preparation and lyophilization for same

Info

Publication number
SG11202000996UA
SG11202000996UA SG11202000996UA SG11202000996UA SG11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA SG 11202000996U A SG11202000996U A SG 11202000996UA
Authority
SG
Singapore
Prior art keywords
lyophilization
antibody
same
drug conjugate
conjugate preparation
Prior art date
Application number
SG11202000996UA
Inventor
Tetsuo KAMII
Norihiro Nishimoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11202000996UA publication Critical patent/SG11202000996UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202000996UA 2017-08-23 2018-08-22 Antibody-drug conjugate preparation and lyophilization for same SG11202000996UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017160071 2017-08-23
PCT/JP2018/030882 WO2019039483A1 (en) 2017-08-23 2018-08-22 Antibody-drug conjugate preparation and lyophilization for same

Publications (1)

Publication Number Publication Date
SG11202000996UA true SG11202000996UA (en) 2020-03-30

Family

ID=65438975

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000996UA SG11202000996UA (en) 2017-08-23 2018-08-22 Antibody-drug conjugate preparation and lyophilization for same

Country Status (13)

Country Link
US (1) US20210128741A1 (en)
EP (1) EP3673918A4 (en)
JP (2) JP7204651B2 (en)
KR (1) KR20200044044A (en)
CN (1) CN110944667A (en)
AU (1) AU2018320470A1 (en)
BR (1) BR112020003474A2 (en)
CA (1) CA3073383C (en)
IL (1) IL272721A (en)
MA (1) MA49987A (en)
SG (1) SG11202000996UA (en)
TW (1) TW201919710A (en)
WO (1) WO2019039483A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102537651B1 (en) * 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates
EP3923928A4 (en) * 2019-02-15 2022-11-09 The Regents Of The University Of California Methods for converting colloidal systems to resuspendable/redispersible powders that preserve the original properties of the colloids
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN113365665A (en) * 2019-03-26 2021-09-07 荣昌生物制药(烟台)股份有限公司 anti-Her 2 antibody drug conjugate pharmaceutical formulations
CN113939318A (en) * 2019-05-29 2022-01-14 第一三共株式会社 Formulation of antibody-drug conjugates
WO2021027851A1 (en) * 2019-08-12 2021-02-18 凯惠科技发展(上海)有限公司 Trop2 antibody, preparation method therefor, and conjugate and use thereof
KR20220157998A (en) * 2020-03-25 2022-11-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pharmaceutical Compositions Comprising Antibody Drug Conjugates and Uses Thereof
JP2023523372A (en) * 2020-05-03 2023-06-02 シャンハイ ミラコーケン インコーポレイティド Antibody-drug conjugates and preparations thereof
CN112361726B (en) * 2020-10-27 2022-09-02 北京诺康达医药科技股份有限公司 Freeze-dried preparation water control method and application thereof
JP2023550533A (en) * 2020-12-18 2023-12-01 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Antibody-drug conjugate targeting B7-H3, its production method and use
WO2023066251A1 (en) * 2021-10-19 2023-04-27 同宜医药（苏州）有限公司 Conjugate drug preparation, preparation method therefor and use thereof
WO2024041587A1 (en) * 2022-08-25 2024-02-29 启德医药科技（苏州）有限公司 Pharmaceutical composition of antibody drug conjugate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
ATE458007T1 (en) 1998-04-20 2010-03-15 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
NZ531426A (en) 1999-06-25 2005-10-28 Genentech Inc Method of treating cancer wherein the cancer expresses epidermal growth factor receptor comprising administration of humanized anti-ErbB2 antibodies
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
WO2003038043A2 (en) 2001-11-01 2003-05-08 Uab Research Foundation Combinations of dr5 antibody and other therapeutic agents
US20060246060A1 (en) 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
MX369959B (en) * 2003-05-14 2019-11-27 Immunogen Inc Drug conjugate composition.
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
SI2129396T1 (en) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CA3150199A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
TW201247222A (en) * 2011-04-21 2012-12-01 Daiichi Sankyo Co Ltd Antibody liquid formulation
LT2907824T (en) * 2012-10-11 2018-06-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate
ES2782248T3 (en) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure
JP6366111B2 (en) 2012-12-13 2018-08-01 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Administration of immunoconjugate consisting of antibody and SN-38 for improved efficacy and reduced toxicity
SG10201707633VA (en) * 2013-03-15 2017-11-29 Abbvie Deutschland Anti-egfr antibody drug conjugate formulations
EP3060256B1 (en) 2013-10-25 2019-05-08 Bayer Pharma Aktiengesellschaft A novel stable formulation
HUE042512T2 (en) 2013-12-25 2019-07-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
HRP20211848T1 (en) 2014-01-31 2022-03-04 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
JP2017114763A (en) 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
SG11201607306PA (en) 2014-04-07 2016-09-29 Seattle Genetics Inc Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
KR102239413B1 (en) * 2014-04-10 2021-04-12 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
CN116059395A (en) * 2015-06-29 2023-05-05 第一三共株式会社 Method for selectively producing antibody-drug conjugates
JP6522806B2 (en) * 2015-07-10 2019-05-29 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Composition comprising antibody duocarmycin drug conjugates
WO2018066626A1 (en) * 2016-10-07 2018-04-12 第一三共株式会社 Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
TW201828993A (en) * 2016-12-12 2018-08-16 日商第一三共股份有限公司 Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (en) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates
AU2018327171B2 (en) * 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
JP7248578B2 (en) * 2017-08-31 2023-03-29 第一三共株式会社 Novel methods for producing antibody-drug conjugates
CA3101906A1 (en) * 2018-05-28 2019-12-05 Daiichi Sankyo Company, Limited Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
KR20210038904A (en) * 2018-07-25 2021-04-08 다이이찌 산쿄 가부시키가이샤 Effective method for preparing antibody-drug conjugates
WO2020027100A1 (en) * 2018-07-31 2020-02-06 第一三共株式会社 Treatment of metastatic brain tumor by administration of antibody-drug conjugate
AU2019320336A1 (en) * 2018-08-06 2021-03-04 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor

Also Published As

Publication number Publication date
AU2018320470A1 (en) 2020-02-13
CA3073383A1 (en) 2019-02-28
JPWO2019039483A1 (en) 2020-10-01
KR20200044044A (en) 2020-04-28
CA3073383C (en) 2023-10-31
IL272721A (en) 2020-04-30
WO2019039483A1 (en) 2019-02-28
JP2023036900A (en) 2023-03-14
RU2020111448A3 (en) 2021-11-29
BR112020003474A2 (en) 2020-10-20
EP3673918A4 (en) 2021-05-19
US20210128741A1 (en) 2021-05-06
CN110944667A (en) 2020-03-31
TW201919710A (en) 2019-06-01
MA49987A (en) 2020-07-01
JP7204651B2 (en) 2023-01-16
RU2020111448A (en) 2021-09-24
EP3673918A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
IL272721A (en) Antibody-drug conjugate preparation and lyophilization for same
IL268102A (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
ZA202003833B (en) Conjugates and preparation and use thereof
EP3626825A4 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
IL290959A (en) Antibody-drug conjugate compisitions and methods for producing same
IL291337A (en) Camptothecin derivative and conjugate thereof
ZA202001219B (en) Bcma monoclonal antibody-drug conjugate
EP3473270A4 (en) Antibody-drug conjugate
HK1231367A1 (en) Antibody-drug conjugates, their preparation and their therapeutic use
SG11202101719PA (en) Antibody-drug conjugate and application thereof
IL253712B (en) Hemiasterlin derivatives for conjugation and therapy
EP3380126A4 (en) Antibody-drug conjugates comprising branched linkers and methods related thereto
HK1243957B (en) Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof
EP3501548A4 (en) Tissue factor-targeted antibody-drug conjugate
EP3412315A4 (en) Anti-her2 antibody-drug conjugate and application thereof
EP3617218A4 (en) Dihydroartemisinin-steroid conjugate and preparation method and use thereof
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
EP3599249A4 (en) Anti-5t4 antibody-drug conjugate and use thereof
IL265838A (en) Cysteine modified antibody-drug conjugate and preparation method thereof
IL277791A (en) Hsp90-targeting conjugates and formulations thereof
IL269321A (en) Drug-polymer conjugate
IL266112A (en) Anti-edb antibodies and antibody-drug conjugates
FI3666787T3 (en) Antibody-drug conjugates including hemiasterlin derivative
EP3441088A4 (en) Antibody-drug conjugate comprising modified antibody
EP3666788A4 (en) Hemiasterlin derivatives and antibody-drug conjugates including same